Please provide your email address to receive an email when new articles are posted on . Adults taking oral fenofibrate had a 27% reduction in diabetic eye disease progression over 4 years. Fenofibrate ...

Use of the cholesterol-lowering drug fenofibrate had a modest but statistically significant association with reduced risk of vision-threatening diabetic retinopathy (VTDR), according to results of a ...

WHAT: A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" ...

The study was a randomized, placebo-controlled comparison of the effects of daily treatment with fenofibrate 160 mg, ezetimibe-simvastatin 10/20 mg, ezetimibe-simvastatin 10/20 mg plus fenofibrate 160 ...

The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative 27% over 4 years compared with placebo (22.7% vs 29.2%, P=0.006), reported David Preiss, MBChB, PhD, of the ...

CLEVELAND — Fenofibrate, patented in 1969 and in medical use since 1975, is well-established as a cholesterol-lowering treatment. However, University Hospitals scientists believe it may also have the ...

Q: The doctor added fenofibrate to my meds because I had high triglycerides (400-plus). Within six weeks, my triglycerides were down to 179. As an extra benefit, the uncontrolled diarrhea I’ve been ...

The resurgence of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to renewed efforts to find effective antivirals, ...

DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the ...

ORLANDO, Fla. — The old, generic cholesterol drug fenofibrate has shown potential for slowing the progression of diabetic retinopathy in people with early retinal changes, with the potential to reduce ...